Introduction
Aortic graft infection is among the most dreaded complications in vascular surgery. Regardless of management, it leads to high morbidity and mortality. Successful treatment traditionally involves removal of the infected prosthesis and revascularisation of the lower extremities by an extra-anatomic bypass. >3 Initial reviews of institutional series of patients with aortic graft infection emphasised the immediate postoperative mortality and morbidity.
The long-term success of conventional treatment is measured in terms of patient survival, limb salvage and the abscence of complications related to graft excision, for example aortic stump blow-out. 4 
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As a treatment option for selected patients -no clinical evidence of septicaemia or retroperitoneal purulent collections and no bacteriological evidence of pseudomonas infection-many vascular surgeons now prefer in situ graft replacement of an infected aortic graft. ~>~9 Its long-term success should be measured in terms of persistent retroperitoneal infections that can develop even years after graft replacement. Late infectious complications most commonly arise in patients with primary graft infections caused by the less virulent micro-organism, for example coagulasenegative Staphylococcus epidermidis. 19 Hence the need for clinical and diagnostic imaging follow-up for reliable retroperitoneal surveillance. Newly introduced functional diagnostic techniques capable of detecting graft infections in their early stages, notably leukocytelabelled 99m HMPAO Technetium Scintigraphy (99m-Tc), seem to meet this requirement. 2°- 22 We report a long-term follow-up (mean 37 months) of 18 patients, nine with an aortoenteric erosion (AEE) * Please address all correspondence to: F. Speziale, University of Rome, "La Sapienza" 00161, Rome, Italy. and nine with a perigraft infection (PGI), who underwent excision of the infected aortofemoral graft and in situ polytetrafluoroethylene (PTFE) graft replacement.
Materials and Methods
We retrospectively reviewed the clinical data of all patients who underwent in situ graft replacement for AEE and PGI at the Department of Vascular Surgery, University of Rome, "La Sapienza" between November 1989 and March 1995. Data analysed included original graft reconstruction, clinical presentation, preoperative diagnosis, operative management, bacteriological cultures of explanted material, early and late complications, survival and limb salvage rate.
Recurrence or persistent infection were defined as the new onset of clinical symptoms (fever, leukocytosis, groin sinus tract) or imaging evidence of infection (99m-Tc scan leukocytes uptake, computed tomography (CT) detected retroperitoneal collection). A mean 37 month follow-up (8-59 months) was obtained from 3-monthly clinical and biochemical assessments (erythrocyte sedimentation rate, white blood cell count), a 6-monthly 99m-Tc scan for the first year and yearly thereafter. Patients with uncertain 99m-Tc scan findings underwent a CT scan.
Results
During the 4.5-year study period, 18 patients (17 men and one woman, mean age of 64.7 years, range 31-77 years) underwent in situ PTFE graft replacement, nine patients for AEE and nine patients PGI. Eleven patients had their original aortic reconstruction at our department and seven elsewhere. Eight (44.4%) had originally undergone surgery for occlusive arterial 1078-5884/97/SA0111+04 $12.00/0 © 1997 W.B. Saunders Company Ltd. disease, 10 (55.6%) for infrarenal aortic aneurysms, one a ruptured aneurysm. All original surgical procedures were done with knitted Dacron grafts, under perioperative antibiotic coverage. Twelve patients had originally received aortomonofemoral or aortobifemoral bypass grafts; five had aortoaortic grafts and one an aortobi-iliac graft. All patients had an uncomplicated postoperative course. The mean interval between graft placement and diagnosis of graft infections was 46 months (range 6-77).
Clinical examination showed that all patients were haemodynamically stable. None required emergency treatment. The most frequent symptom was intermittent fever (12 patients, 66.6%), seven patients reported gastrointestinal bleeding: four had occult faecal blood and three referred a single episode of melaena with an average onset 20 days before admittance. Eleven patients (61.1%) also had groin symptoms: five cases (41.6%) cutaneous sinus tracts, three (25%) abscesses, and three (25%) false anastomotic aneurysms. CT scans, obtained in all subjects at admittance, showed that 13 patients (72.2%) had evidence of periprosthetic infection (gas bubbles, periprosthetic inflammatory reactions) but none of them had gross retroperitoneal collections. Magnetic resonance imaging (MRI), obtained in eight cases, showed that six patients (75%) had evident signs of prosthetic graft infection. In all 18 patients (100%), scintigraphy with 99m-Tc scan revealed a pathological leukocyte accumulation along the entire graft. Arteriograms were obtained in all patients for planning surgical treatment. The seven patients who had previous gastrointestinal bleeding underwent upper gastrointestinal endoscopy (UGIE) as the first diagnostic intervention. Six of them (85.7%) had aorto-enteric erosions in the third or fourth portion of the duodenum.
The operative procedure comprised excision of the prosthetic graft and immediate in situ replacement with a standard PTFE graft. None of the infected prosthetic grafts adhered closely to the surrounding tissues, none had unduly large purulent collections, and none of the proximal aortic anastomoses showed signs of suture-line dehiscence. Nine patients had "AEEs. In these patients, before vascular surgery, the duodenal lesion was repaired, in six cases by duodenal deepening with a simple suture and in three cases with a resection of the third part of the duodenum and end-to-end intestinal anastomosis. Before in situ placement of the PTFE graft, the surrounding necrotic tissues were debrided as thoroughly as possible and the field washed repeatedly with an antiseptic solution containing 2% povidine-iodine. In patients with AEE, we isolated the new prosthesis from the duodenum by inserting an omental wrap. All patients received intravenous antibiotic therapy for 6 weeks postoperatively, followed by a 2-week course of oral therapy.
Two of the 18 patients died during the postoperative course: the first on the second postoperative day after a myocardial infarction and the other, a patient with an AEE, on postoperative day 19 because of haemorrhagic shock. Autopsy revealed dehiscence of the proximal anastomosis. None of the remaining 16 operations resulted in perioperative deaths, none of the prosthetic branches became thrombosed and no amputations were needed. During a mean follow-up of 37 months (range 8-59 months), none of our 16 surviving patients had infectious complications related to the new graft. Preoperative 99m-Tc scan obtained 6 months after in situ replacement showed that 13 patients (81.2%) had complete disappearance of leukocyte accumulations. The remaining three patients (18.8%) had reduced accumulations. Repeat 12 month postoperative scans showed no further leukocyte uptake along the grafts. Two patients had thrombectomy of a graft limb, 4 and 12 months after replacement. One patient died of a lung neoplasm after graft replacement but had no evidence of graft-related complications.
Discussion
The most widely accepted surgical management option for aortofemoral graft infections consists of removal of the infected prosthesis followed by aortic ligation and extra-anatomic revascularisation of the lower limbs. This procedure has gradually improved results so that current perioperative mortality ranges from 14 to 29%, the incidence of amputation from 13 to 29%. 4-9 But it also puts patients at risk for late complications linked to aortic ligation, wound dehiscence or aortic pseudoaneurysms. The few series with a long-term follow-up (35-60 months) also report a 10-15% incidence of retroperitoneal reinfection. 1° The extra-anatomic bypass procedure alone places patients at generic risk of graft-related complications (thrombosis, infection and embolisation) that necessitate amputation. 23' 24 The risk of thrombosis or a reinfected axillofemoral bypass ranges from 5 to 30%. In a series of 51 patients with PGI and 33 with graft-enteric fistula and a 5-year follow-up, O'Hara et al. 6 reported a survival of 18% and an amputation rate of 27%. They also noted that although perigraft infection patients had significantly greater 30-day survival curves than patients with graft-enteric fistula (85% vs. 49%), their 1-year survival curves became similar (47% vs. 35%).
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In a series of 28 patients, with a mean 44-month followup, Yeager et al. 7 reported an extra-anatomic bypass reinfection rate of 22% and an amputation rate of 24%. In a 35-month follow-up of 30 patients who survived aortic ligation and extra-anatomic bypass, QuinonesBaldrich et al. 8 reported a mortality of 20% and an amputation rate of 22%.
Encouraged by the good outcome obtaIned by others 25"26 we have used in situ graft replacement as an alternative to graft removal. Current evidence suggests that the in situ procedure is clinically contraindicated in patients with septicaemia or retroperitoneal abscesses, n' 13' 15 and bacteriologically contraindicated in all patients with pseudomonas infections. ~s'6 Long-term results from studies using these indications suggest a graft-reinfection rate ranging from 5 to 14%. Reinfections developed in patients with aortobifemoral bypasses and localised groin symptoms, who had undergone replacement of the clinically infected graft branch aloneY ' 19 From the technical viewpoint, we based our decision to perform total graft removal less on clinical criteria than on 99m-Tc scan data. Even in patients who had clinical symptoms localised to the groin, some scans clearly showed leukocyte uptake also in the proximal anastomosis, and bacteriological cultures subsequently confirmed these findings. Radical surgery may explain why in our patients the recurrent infections commonly reported by others did not develop.
Although the ideal material for in situ replacement grafts remains controversial, most vascular surgeons have used Dacron grafts, 12-14 and recent papers have described the experimental and clinical use of Dacron prostheses impregnated with rifampicin. ~7' 27 In 1991, Bahnini et al. 28 reported the first case of an infected aortic graft replaced with a prosthesis made from the aorta taken from a cadaver. In 1993 they reported promising results obtained using this method in a series of 58 artic graft infections. 29 The immediate results after homologous tissue transplantation indicated a perioperative mortality rate of 13.8% with no major amputation; during a 19.6-month follow-up (range 14-33 months) only one patient died because of reinfection, whereas 24% of the patients had complications (including aortoiliac dilatation and iliofemoral steno-occlusive lesions) directly related to the type of homologous graft material. If future research solves the immunological problems thought responsible for complications, then synthetic grafts might be abandoned in favour of homologous grafts. In 1995, Nevelsteen et al. 3° reported autogenous reconstruction with the superficial femoral vein in 12 patients with prosthetic infection after aorto (ilio)-femoral grafting. A mean 17-month follow-up showed no reinfections, one occluded graft, and minimal disability from removal of the deep veins. Although autogenous reconstruction promises to save life and limb, a longer period of follow-up is required to study the long-term behaviour of these grafts and to allow definitive comparison with the more conventional approaches. Since 1989 we have used grafts made of PTFE because the bacteria that most commonly cause primary graft infections adhere much less easily to PTFE than to Dacron. 31 Our analysis of postoperative morbidity showed that none of our patients needed limb amputation; in two patients who developed a graft limb thrombosis, thrombectomy followed by anticoagulant therapy resolved the problem. One patient died of a neoplasm 44 months after graft replacement and had no signs of reinfection. During the 37-month follow-up no patient had evidence of graft reinfection. The surveillance protocol for new grafts implanted in patients undergoing in situ replacement comprised 3-monthly clinical assessment and 6-monthly 99m-Tc scans for the first postoperative year and annually thereafter. Of the imaging techniques used in the diagnosis of graft infections, 99m-Tc scanning seems highly reliable and will detect bacterial contamination already in the first months after original graft implantation. 21 Pathogenspecific antibiotic therapy started as soon as possible and prolonged postoperatively is essential to prevent reinfection. Our patients receive intravenous antibiotics for 6 weeks, and oral therapy for at least 2 weeks. Serum samples are tested regularly to monitor the efficacy of therapy.
Conclusions
An infected aortic graft remains an unwelcome event. Nonetheless, surgical treatment offers far better prospects now than it did in the past. The improved surgical outcome has shifted attention to problems related to the long-term surveillance of surviving patients. After conventional surgery and in situ replacement, a meticulous retroperitoneal surveillance protocol is needed to detect reinfections (including pseudoaneurysms of the aortic stump and purulent fluid collections) in their early stages before retroperitoneal bleeding develops. Of the currently available techniques, leukocyte-labelled 99m-Tc scintigraphy has proved diagnostically reliable and fulfills this purpose well. The final question is, how long do these patients need surveillance? Long follow-up is crucial in those with infections caused by low-virulence micro-organisms, for example coagulase-negative Staphylococcus epidermidis.
